Literature DB >> 11124952

Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments.

M Sharma1, M Benharouga, W Hu, G L Lukacs.   

Abstract

Deletion of phenylalanine at position 508 (DeltaF508) is the most common cystic fibrosis (CF)-associated mutation in the CF transmembrane conductance regulator (CFTR), a cAMP-regulated chloride channel. The consensus notion is that DeltaF508 imposes a temperature-sensitive folding defect and targets newly synthesized CFTR for degradation at endoplasmic reticulum (ER). A limited amount of CFTR activity, however, appears at the cell surface in the epithelia of homozygous DeltaF508 CFTR mice and patients, suggesting that the ER retention is not absolute in native tissues. To further elucidate the reasons behind the inability of DeltaF508 CFTR to accumulate at the plasma membrane, its stability was determined subsequent to escape from the ER, induced by reduced temperature and glycerol. Biochemical and functional measurements show that rescued DeltaF508 CFTR has a temperature-sensitive stability defect in post-ER compartments, including the cell surface. The more than 4-20-fold accelerated degradation rate between 37 and 40 degrees C is, most likely, due to decreased conformational stability of the rescued DeltaF508 CFTR, demonstrated by in situ protease susceptibility and SDS-resistant thermoaggregation assays. We propose that the decreased stability of the spontaneously or pharmacologically rescued mutant may contribute to its inability to accumulate at the cell surface. Thus, therapeutic efforts to correct the folding defect should be combined with stabilization of the native DeltaF508 CFTR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11124952     DOI: 10.1074/jbc.M009172200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  96 in total

Review 1.  Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis.

Authors:  Marina S Gelman; Ron R Kopito
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  Thermal instability of ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) channel function: protection by single suppressor mutations and inhibiting channel activity.

Authors:  Xuehong Liu; Nicolette O'Donnell; Allison Landstrom; William R Skach; David C Dawson
Journal:  Biochemistry       Date:  2012-06-15       Impact factor: 3.162

3.  Pyrazolylthiazole as DeltaF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles.

Authors:  Long Ye; John M Knapp; Panjamaporn Sangwung; James C Fettinger; A S Verkman; Mark J Kurth
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

4.  Side chain and backbone contributions of Phe508 to CFTR folding.

Authors:  Patrick H Thibodeau; Chad A Brautigam; Mischa Machius; Philip J Thomas
Journal:  Nat Struct Mol Biol       Date:  2004-12-26       Impact factor: 15.369

5.  Effect of rapamycin on the fate of P23H opsin associated with retinitis pigmentosa (an American Ophthalmological Society thesis).

Authors:  Shalesh Kaushal
Journal:  Trans Am Ophthalmol Soc       Date:  2006

6.  Impact of salt exposure on N-acetylgalactosamine-4-sulfatase (arylsulfatase B) activity, glycosaminoglycans, kininogen, and bradykinin.

Authors:  Kumar Kotlo; Sumit Bhattacharyya; Bo Yang; Leonid Feferman; Shah Tejaskumar; Robert Linhardt; Robert Danziger; Joanne K Tobacman
Journal:  Glycoconj J       Date:  2013-02-06       Impact factor: 2.916

7.  Conditional JAG1 mutation shows the developing heart is more sensitive than developing liver to JAG1 dosage.

Authors:  Fengmin Lu; Jennifer J D Morrissette; Nancy B Spinner
Journal:  Am J Hum Genet       Date:  2003-03-14       Impact factor: 11.025

8.  SYVN1, NEDD8, and FBXO2 Proteins Regulate ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitin-mediated Proteasomal Degradation.

Authors:  Shyam Ramachandran; Samantha R Osterhaus; Kalpaj R Parekh; Ashley M Jacobi; Mark A Behlke; Paul B McCray
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

9.  Click-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis.

Authors:  Michael B Donald; Kevin X Rodriguez; Hannah Shay; Puay-Wah Phuan; A S Verkman; Mark J Kurth
Journal:  Bioorg Med Chem       Date:  2012-07-06       Impact factor: 3.641

10.  Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator.

Authors:  Martina Gentzsch; Xiu-Bao Chang; Liying Cui; Yufeng Wu; Victor V Ozols; Amit Choudhury; Richard E Pagano; John R Riordan
Journal:  Mol Biol Cell       Date:  2004-04-09       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.